According to the study, participants taking Zepbound lost an average of 20.2% of their starting weight after 72 weeks, ...

The weight-loss market began feeling some growing pains as the year ended, creating more wariness for the upcoming year. For ...

“Zepbound, as expected, was more effective in promoting weight loss. While Wegovy caused an average weight loss of 13.7% body weight, Zepbound promoted around 20.2% body weight loss in patients.

Zepbound got FDA approval to treat obesity and weight loss in November 2023 ... These include white papers, government data, original reporting, and interviews with industry experts.

On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro ... "I’m just not persuaded that the data on which FDA is relying ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

GLP-1 class drugs like Zepbound and Mounjaro form part of a larger group of products like Wegovy and Ozempic from Novo Nordisk that have shown results in helping people lose weight. With demand ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

Zepbound, as expected, was more effective in promoting weight loss. Eli Lilly's Zepbound drug ... according to GlobalData, a leading data and analytics company. It has been a year since the ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.

But since current data suggests Zepbound’s ability to tame OSA symptoms is directly tied to weight loss, Dr. Dasgupta notes it is likely to benefit a small subset of patients who have sleep ...